Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 23 for “"Advanced therapy"”.

  1. The economics of manufacturing clinical-grade advanced therapy medicinal products (ATMPs)

    … addition to conventional drugs and biologicals, advanced therapy medicinal products (ATMP) represents a new class of medicinal products, which include - amongst others - somatic cell therapeutics. As the final product is intended for administration into humans, manufacturers of ATMPs are …

    fu-berlin Repository record for The economics of manufacturing clinical-grade advanced therapy medicinal products (ATMPs) (opens in a new tab)

  2. Advanced therapy medicinal products in retinal diseases: a focus on age-related macular degeneration

    Η ηλικιακή εκφύλιση της ωχράς κηλίδας (AMD) είναι η κύρια αιτία διαταραχής της όρασης παγκοσμίως, επηρεάζοντας κυρίως τον ηλικιωμένο πληθυσμό. Χαρακτηρίζεται από προοδευτική εκφύλιση της ωχράς κηλίδας, που οδηγεί στη σταδιακή απώλεια της κεντρικής όρασης. Η AMD επηρεάζεται από έναν συνδυασμό …

    athens Repository record for Advanced therapy medicinal products in retinal diseases: a focus on age-related macular degeneration (opens in a new tab)

  3. Investigating and Guiding Evidence Generation to Inform Regulatory Decision-Making for Advanced Therapy Medicinal Products (ATMPs)

    Advanced Therapy medicinal products (ATMPs) are a novel, diverse group of pharmaceuticals that comprise cell therapies, gene therapies, and tissue-engineered products. ATMPs have provided new therapeutic approaches for several unmet medical needs. However, approved ATMPs in the EU have shown a …

    fu-berlin Repository record for Investigating and Guiding Evidence Generation to Inform Regulatory Decision-Making for Advanced Therapy Medicinal Products (ATMPs) (opens in a new tab)

  4. Συμφωνίες βάσει αποτελεσμάτων για ATMPs και εύλογη αξία σε θεραπείες μακροχρόνιας αποτελεσματικότητας / Outcome-based agreements for ATMPs: fair value assesment in long-latency therapies

    … εξετάζει την επίδραση των προηγμένων θεραπειών (Advanced Therapy Medicinal Products – ATMPs) στους μηχανισμούς τιμολόγησης και αποζημίωσης των συστημάτων υγείας, με έμφαση στις συμφωνίες βάσει αποτελέσματος (outcome-based agreements). Στόχος είναι η διερεύνηση του τρόπου με τον οποίο οι θεραπείες …

    athens Repository record for Συμφωνίες βάσει αποτελεσμάτων για ATMPs και εύλογη αξία σε θεραπείες μακροχρόνιας αποτελεσματικότητας / Outcome-based agreements for ATMPs: fair value assesment in long-latency therapies (opens in a new tab)

  5. Žmogaus mezenchiminių kamieninių ląstelių genetinių savybių tyrimas saugiai terapijai užtikrinti /

    Human mesenchymal stem cell (MSC) therapy holds promise for treating degenerative and immune system diseases and repair of damaged tissues. Human tissues are cryopreserved and isolated MSCs are expanded in various culture media when prepared for clinical applications. These manipulations can …

    vilnius Repository record for Žmogaus mezenchiminių kamieninių ląstelių genetinių savybių tyrimas saugiai terapijai užtikrinti / (opens in a new tab)

  6. Investigation of human mesenchymal stem cell genetic characteristics to ensure therapy safety /

    Human mesenchymal stem cell (MSC) therapy holds promise for treating degenerative and immune system diseases and repair of damaged tissues. Human tissues are cryopreserved and isolated MSCs are expanded in various culture media when prepared for clinical applications. These manipulations can …

    vilnius Repository record for Investigation of human mesenchymal stem cell genetic characteristics to ensure therapy safety / (opens in a new tab)

  7. Σύγκριση ρυθμιστικών πλαισίων GMP μεταξύ Ευρώπης και ΗΠΑ για βιοτεχνολογικά και γονιδιακά φάρμακα με έμφαση στη διαχείριση κινδύνων

    … και μελέτες περίπτωσης εγκεκριμένων ATMPs (Advanced Therapy Medicinal Products), αναδεικνύονται τόσο οι κοινές αρχές όσο και οι ουσιώδεις διαφορές ανάμεσα στις δύο προσεγγίσεις. Ο FDA υιοθετεί μια πιο ευέλικτη, τεκμηριωμένη βάση, ενώ ο EMA εστιάζει σε πιο δομημένες και τυποποιημένες …

    athens Repository record for Σύγκριση ρυθμιστικών πλαισίων GMP μεταξύ Ευρώπης και ΗΠΑ για βιοτεχνολογικά και γονιδιακά φάρμακα με έμφαση στη διαχείριση κινδύνων (opens in a new tab)

  8. EQUINE PITUITARY PARS INTERMEDIA DYSFUNCTION (PPID): PATHOPHYSIOLOGY AND A SURGICAL APPROACH TO TREATMENT

    … specific aims were to confirm the need for this advanced therapy by determining the prevalence of PPID in horses globally; to continue the investigation of the underlying cellular mechanism of PPID by confirming the role of pro-hormone convertases, and sequence the equine pro-opiomelanocortin, …

    sask Repository record for EQUINE PITUITARY PARS INTERMEDIA DYSFUNCTION (PPID): PATHOPHYSIOLOGY AND A SURGICAL APPROACH TO TREATMENT (opens in a new tab)

  9. Engineered silk hydrogels for the delivery of mesenchymal stem cells to the stroked brain

    … potential to be deployed as a delivery matrix in advanced cell-based therapies (Chapter 1). My principle hypothesis is that silk can be engineered into hydrogels to mimic the structure and function of the native extracellular matrix [ECM], ultimately influencing cellular biology. The aim of this …

    strathclyde Repository record for Engineered silk hydrogels for the delivery of mesenchymal stem cells to the stroked brain (opens in a new tab)

  10. Standardanalysepanel zur immunphänotypischen Charakterisierung von klassischen und neuartigen Zelltherapeutika sowie ATMPs mit und ohne Stammzellen

    … von Arzneimitteln für neuartige Therapien (Advanced Therapy Medicinal Products, ATMPs). Während die frühere Analytik beispielsweise auf die Stammzellbestimmung der Kolonie-bildenden Einheiten (CFU-Assay) oder die Drei- Farben-Durchflusszytometrie sowie auf die Sterilkontrolle setzte, sind …

    fu-berlin Repository record for Standardanalysepanel zur immunphänotypischen Charakterisierung von klassischen und neuartigen Zelltherapeutika sowie ATMPs mit und ohne Stammzellen (opens in a new tab)

  11. Machine Learning and Decision Making to Optimize Treatment Planning in Parkinson’s Disease

    … L-dopa increase in severity, patients may need advanced therapies such as deep brain stimulation (DBS), a neurosurgical treatment. Advanced therapies have been shown effective at alleviating the side effects associated with L-dopa. However, DBS requires the additional tuning of stimulation …

    utk-theses Repository record for Machine Learning and Decision Making to Optimize Treatment Planning in Parkinson’s Disease (opens in a new tab)

  12. Cryopreservation of human vascular umbilical cord cells under good manufacturing practice conditions for future cell banks

    … quality control. For the future fabrication of advanced therapy medicinal products consisting of these cells, GMP conditions are required by the regulatory authority.

    fu-berlin Repository record for Cryopreservation of human vascular umbilical cord cells under good manufacturing practice conditions for future cell banks (opens in a new tab)

  13. Clinical evaluation of CAP7.1 in therapy refractory biliary tract cancer in a randomized phase II trial

    … die within 10 years while most receive chemotherapy at some stage. Life expectancy under Gemcitabine/Cisplatin 1st-line-standard (median-overall-survival [mOS]: 11.7m, median-progression-free-survival [mPFS]: 8.0m) and in 2nd-line (mOS: 5-7m, mPFS: 3m) is limited while no 2nd-line standard …

    fu-berlin Repository record for Clinical evaluation of CAP7.1 in therapy refractory biliary tract cancer in a randomized phase II trial (opens in a new tab)

  14. Surgery for inflammatory bowel disease in the era of advanced medical therapy

    … IBD has classically involved the use of medical therapy to induce and maintain remission with surgery reserved for disease that is refractory to medical therapy or where irreversible complications have occurred. Treatment was historically limited to corticosteroids and immunomodulators such as …

    edinburgh Repository record for Surgery for inflammatory bowel disease in the era of advanced medical therapy (opens in a new tab)

  15. STUDIO DI ANALISI DEL RISCHIO E CONVALIDA DEI PROCESSI DI PRODUZIONE DI FARMACI INIETTABILI PER LE TERAPIE AVANZATE

    Advanced therapies include gene therapy products, cellular and tissue engineering. These "products" contain living cells or complex parts of them appropriately manipulated to "alter" the genetic, physiological or biological tissue / organ treated. The work, performed during the PhD, was addressed …

    milano Repository record for STUDIO DI ANALISI DEL RISCHIO E CONVALIDA DEI PROCESSI DI PRODUZIONE DI FARMACI INIETTABILI PER LE TERAPIE AVANZATE (opens in a new tab) Restricted access

  16. Engineering optimal culture conditions to trans-differentiate dermal fibroblasts towards tenogenic lineage

    … technology for the accelerated development of advanced therapy medicinal products. In addition, during this study, it was detected that human tenocytes produced higher amounts of TGFB2 than dermal fibroblasts, highlighting this growth factor as a potential tool to shift the dermal fibroblast …

    greece Repository record for Engineering optimal culture conditions to trans-differentiate dermal fibroblasts towards tenogenic lineage (opens in a new tab)

  17. Η εξέλιξη των ρυθμιστικών πλαισίων για τις θεραπείες προηγμένης ιατρικής (ATMPs) και η επίδρασή τους στην πρόσβαση των ασθενών / The evolution of regulatory frameworks for advanced medicines therapies (ATMPs) and their impact on patient access

    Οι Προηγμένες Θεραπείες (Advanced Therapy Medicinal Products – ATMPs) αποτελούν μία από τις σημαντικότερες εξελίξεις της σύγχρονης βιοϊατρικής επιστήμης και της φαρμακευτικής καινοτομίας. Οι θεραπείες αυτές περιλαμβάνουν τις γονιδιακές θεραπείες, τις σωματικές κυτταρικές θεραπείες, τα προϊόντα …

    athens Repository record for Η εξέλιξη των ρυθμιστικών πλαισίων για τις θεραπείες προηγμένης ιατρικής (ATMPs) και η επίδρασή τους στην πρόσβαση των ασθενών / The evolution of regulatory frameworks for advanced medicines therapies (ATMPs) and their impact on patient access (opens in a new tab)

  18. Entwicklung eines bioartifiziellen Rekonstruktionsgewebes für die Luftröhrenchirugie und Umsetzung in einen GMP-Prozess

    Das Ziel dieser Arbeit war die Entwicklung eines vaskularisierten, autologen Implantats zur Behandlung von schweren Verletzungen der Trachea im Umfeld der guten Herstellungspraxis. Die Matrix besteht aus einem circa 14 cm langen Stück porcinen, azellularisierten Dünndarm und BioVaSc (Biological …

    wurz-thes Repository record for Entwicklung eines bioartifiziellen Rekonstruktionsgewebes für die Luftröhrenchirugie und Umsetzung in einen GMP-Prozess (opens in a new tab)

Page 1 of 2